MAPPING OF THE P53 AND MDM-2 INTERACTION DOMAINS

被引:650
作者
CHEN, JD [1 ]
MARECHAL, V [1 ]
LEVINE, AJ [1 ]
机构
[1] PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544
关键词
D O I
10.1128/MCB.13.7.4107
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 90-kDa cellular protein encoded by the mouse mdm-2 oncogene binds to the p53 protein in vivo and inhibits its transactivation function (J. Momand, G. P. Zambetti, D. C. Olson, 1). George, and A. J. Levine, Cell 69:1237-1245, 1992). cDNA clones encoding the human homolog of the mdm-2 protein (also called hdm-2) were isolated from a HeLa cell cDNA library. A series of monoclonal antibodies have been generated against human mdm-2 protein, and the epitopes recognized by these antibodies have been mapped. By construction of a series of deletion mutants, the region of the mdm-2 protein that is critical for complex formation with the p53 protein has been mapped to the N-terminal portion of the human mdm-2 protein. Interestingly, a monoclonal antibody with an epitope located in this same region failed to immunoprecipitate the mdm-2-p53 complex and appeared to recognize only free mdm-2 protein. The domain of the p53 protein that is sufficient for interaction with human mdm-2 protein has been mapped to the N-terminal 52 amino acid residues of the p53 protein. This region contains the transactivation domain of p53, suggesting that mdm-2 may inhibit p53 function by disrupting its interaction with the general transcription machinery.
引用
收藏
页码:4107 / 4114
页数:8
相关论文
共 51 条
[1]   SITE-SPECIFIC BINDING OF WILD-TYPE-P53 TO CELLULAR DNA IS INHIBITED BY SV40-T ANTIGEN AND MUTANT P53 [J].
BARGONETTI, J ;
REYNISDOTTIR, I ;
FRIEDMAN, PN ;
PRIVES, C .
GENES & DEVELOPMENT, 1992, 6 (10) :1886-1898
[2]   MOLECULAR ANALYSIS AND CHROMOSOMAL MAPPING OF AMPLIFIED GENES ISOLATED FROM A TRANSFORMED MOUSE 3T3-CELL LINE [J].
CAHILLYSNYDER, L ;
YANGFENG, T ;
FRANCKE, U ;
GEORGE, DL .
SOMATIC CELL AND MOLECULAR GENETICS, 1987, 13 (03) :235-244
[3]   MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221
[4]   WILD-TYPE P53 CAN INHIBIT ONCOGENE-MEDIATED FOCUS FORMATION [J].
ELIYAHU, D ;
MICHALOVITZ, D ;
ELIYAHU, S ;
PINHASIKIMHI, O ;
OREN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8763-8767
[5]  
ELIYAHU D, 1988, ONCOGENE, V3, P313
[6]   TUMORIGENIC POTENTIAL ASSOCIATED WITH ENHANCED EXPRESSION OF A GENE THAT IS AMPLIFIED IN A MOUSE-TUMOR CELL-LINE [J].
FAKHARZADEH, SS ;
TRUSKO, SP ;
GEORGE, DL .
EMBO JOURNAL, 1991, 10 (06) :1565-1569
[7]   WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO [J].
FARMER, G ;
BARGONETTI, J ;
ZHU, H ;
FRIEDMAN, P ;
PRYWES, R ;
PRIVES, C .
NATURE, 1992, 358 (6381) :83-86
[8]   ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE [J].
FINLAY, CA ;
HINDS, PW ;
TAN, TH ;
ELIYAHU, D ;
OREN, M ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) :531-539
[9]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093
[10]   MONOCLONAL-ANTIBODIES SPECIFIC FOR SIMIAN VIRUS-40 TUMOR-ANTIGENS [J].
HARLOW, E ;
CRAWFORD, LV ;
PIM, DC ;
WILLIAMSON, NM .
JOURNAL OF VIROLOGY, 1981, 39 (03) :861-869